论文部分内容阅读
目的探讨初诊2型糖尿病患者采用甘精胰岛素与诺和灵N进行治疗的临床效果,为此类患者的临床治疗提供参考依据。方法选择南乐县人民医院2010年9月至2011年9月收治的120例初诊2型糖尿病患者作为研究对象,所有患者在入院后均给予0.5 mg瑞格列奈进行治疗,每天给药2次,利用随机数字法将其均分为观察组与对照组。观察组患者给予甘精胰岛素进行治疗,对照组患者给予诺和灵N进行治疗,对所有患者治疗前后的相关指标进行比较。结果经过3个月的治疗后,两组患者的糖基化血红蛋白(HbA1c)、餐后血糖(PPG)以及空腹血糖(FPG)均有所下降,两组患者的低血糖发生率、结束时的胰岛素用量存在明显差异,差异有统计学意义(P<0.05)。结论在对初诊2型糖尿病患者进行临床诊断时,甘精胰岛素与诺和灵N均可以对患者的血糖水平进行有效的控制,其中甘精胰岛素在降低胰岛素用量、血糖控制以及低血糖发生情况方面具有明显优势。
Objective To investigate the clinical efficacy of insulin glargine and Novolin N in newly diagnosed type 2 diabetic patients and provide references for the clinical treatment of these patients. Methods 120 patients with newly diagnosed type 2 diabetes admitted to Nanle County People’s Hospital from September 2010 to September 2011 were enrolled. All patients were treated with repaglinide 0.5 mg twice a day after admission , Using random number method to divide them into observation group and control group. Patients in the observation group were given insulin glargine for treatment. Patients in the control group were treated with Novolin N, and all the patients were compared before and after treatment. Results After three months of treatment, the levels of HbA1c, PPG and FPG decreased in both groups. The incidence of hypoglycaemia, There was significant difference in the amount of insulin, the difference was statistically significant (P <0.05). Conclusions Glargine and Novolin N can effectively control the blood glucose level of patients with newly diagnosed type 2 diabetes patients. Glargine exerts significant effects on reducing insulin dosage, blood sugar control and hypoglycemia Has obvious advantages.